"Alzheimer’s disease represents a growing burden to healthcare systems and societies worldwide. This disease is often multifactorial and complex in nature, and we believe that our precision medicine platform and novel central nervous system mechanism improve the chance of clinical success. We are pleased by the results of the placebo-controlled Phase 2b/3 Alzheimer’s disease trial which data suggest that ANAVEX 2-73, an orally available, small-molecule activator of the upstream sigma-1 receptor, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity and might be at the forefront of biomarker-guided pathway-based targeted precision medicine drug development," said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "We look forward to presenting the complete dataset of the study as well as other long-term study data of the other programs, including Parkinson’s disease dementia and Rett syndrome. With a deep portfolio of promising therapies, we believe that Anavex remains well positioned to address the urgent needs of patients affected by neurodegenerative and rare neurodevelopmental diseases."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVXL:
- Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
- Anavex could submit blarcamesine to FDA by year end, says H.C. Wainwright
- Anavex announces exceeding enrollment target for ANAVEX2-73 EXCELLENCE trial
- Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
- Anavex price target raised to $50 from $42 at H.C. Wainwright
